in this phase i trial , bisantrene showed clinical antitumor activity against both hematological cancer ( i.e. , lymphoma and myeloma ) and solid tumors ( i.e. , bladder , lung , and renal cancer and melanoma ) .
C0280100
solid tumors
C0025202
melanoma